Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment.
Kahnert K, Andreas S, Kellerer C, Lutter JI, Lucke T, Yildirim Ö, Lehmann M, Seissler J, Behr J, Frankenberger M, Bals R, Watz H, Welte T, Trudzinski FC, Vogelmeier CF, Alter P, Jörres RA; COSYCONET Study Group. Kahnert K, et al. Among authors: vogelmeier cf. Sci Rep. 2022 Jan 26;12(1):1435. doi: 10.1038/s41598-022-05276-x. Sci Rep. 2022. PMID: 35082306 Free PMC article.
[Genetic lung diseases].
Vogelmeier CF. Vogelmeier CF. Inn Med (Heidelb). 2024 Jun;65(6):531-532. doi: 10.1007/s00108-024-01724-0. Epub 2024 May 29. Inn Med (Heidelb). 2024. PMID: 38811400 German. No abstract available.
Skin Markers of Premature Ageing in Patients with COPD: Results Form COSYCONET.
Melzer T, Graf V, Kronseder A, Karrasch S, Kerschner M, Vogelmeier CF, Bals R, Alter P, Watz H, Fähndrich S, Behr J, Waschki B, Trudzinski FC, Jörres RA, Kahnert K. Melzer T, et al. Among authors: vogelmeier cf. J Clin Med. 2024 Nov 19;13(22):6972. doi: 10.3390/jcm13226972. J Clin Med. 2024. PMID: 39598116
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS).
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM. Bhatt SP, et al. Among authors: vogelmeier cf. Respir Med. 2024 Oct 29:107846. doi: 10.1016/j.rmed.2024.107846. Online ahead of print. Respir Med. 2024. PMID: 39481660 Free article.
Diffusion capacity and static hyperinflation as markers of disease progression predict 3-year mortality in COPD: Results from COSYCONET.
Pott H, Weckler B, Gaffron S, Martin R, Maier D, Alter P, Biertz F, Speicher T, Bertrams W, Jung AL, Laakmann K, Heider D, Wouters M, Vogelmeier CF, Schmeck B; COSYCONET Study Group. Pott H, et al. Among authors: vogelmeier cf. Respirology. 2024 Oct 24. doi: 10.1111/resp.14843. Online ahead of print. Respirology. 2024. PMID: 39448064 Free article.
GOLD-Grade Specific Disease Characterization and Phenotyping of COPD Using Quantitative Computed Tomography in the Nationwide COSYCONET Multicenter Trial in Germany.
Konietzke P, Weinheimer O, Triphan SMF, Nauck S, Wuennemann F, Konietzke M, Jobst BJ, Jörres RA, Vogelmeier CF, Heussel CP, Kauczor HU, Biederer J, Wielpütz MO; COSYCONET study group. Konietzke P, et al. Among authors: vogelmeier cf. Respiration. 2024 Aug 22:1-17. doi: 10.1159/000540781. Online ahead of print. Respiration. 2024. PMID: 39173593
269 results